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SCIENTIFIC OPINION 
Scientific Opinion on a request from the European Commission for the 
assessment of the scientific elements put forward by Luxembourg to 
support the prohibition for the placing on the market of GM potato EH92-
527-1 for cultivation purposes in Luxembourg1 
EFSA Panel on Genetically Modified Organisms2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
 
This scientific output, published on 18 October 2012, replaces the earlier version published on 20 
September 2012 
ABSTRACT 
Luxembourg notified to the European Commission its scientific arguments justifying the implementation of a 
national safeguard measure prohibiting the placing on the market of GM potato EH92-527-1 for cultivation 
purposes in Luxembourg, after which the European Commission asked the European Food Safety Authority 
(EFSA) to assess the scientific information supporting the prohibition. Having considered the information 
package provided by Luxembourg and all relevant scientific publications, the EFSA Panel on Genetically 
Modified Organisms (GMO Panel) concluded that: (i) no new data specific to the safety of the nptII gene have 
been provided; (ii) although bacterial DNA release and development of competence are expected to occur more 
efficiently in biofilms, the link between resistance in biofilms and cultivation/processing of GM potato EH92-
527-1 was not established by Luxembourg, and the main barriers, limiting the transformation frequency of 
bacterial cells with transgenic plant DNA, remain; (iii) the risk posed by the formation of mosaic structures of 
aminoglycoside phosphotransferase genes could not be assessed without data documenting the existence of such 
structures among the existing gene variants, and such data were not provided; (iv) the knowledge gaps and 
uncertainties highlighted in the Luxembourgeois document and the therapeutic relevance of kanamycin and 
neomycin have already been considered in the previous EFSA opinion on antibiotic resistance marker genes, 
and no new information on the safety of nptII gene as present in the GM potato EH92-527-1 has been identified 
in the scientific literature that would cause the GMO Panel to change its previous conclusions. Therefore, the 
EFSA GMO Panel concludes that no grounds exist to date that would lead to reconsideration of its opinion on 
GM potato EH92-527-1. 
© European Food Safety Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Genetically Modified Organisms 
(GMO) was asked to deliver a scientific opinion on the elements put forward by Luxembourg to 
support the prohibition for the placing on the market of GM potato EH92-527-1 for cultivation 
purposes in Luxembourg. 
In July 2011, Luxembourg notified to the EC its scientific argumentation justifying the 
implementation of a national safeguard measure prohibiting the placing on the market of GM potato 
EH92-527-1 for cultivation purposes in Luxembourg, according to Article 23 of Directive 
2001/18/EC on the deliberate release in the environment of genetically modified organisms. 
On 23 May 2012, the European Food Safety Authority (EFSA) has been requested by the European 
Commission to assess the scientific information submitted by the Luxembourgeois Authorities in the 
context of a safeguard clause invoked under Article 23 of Directive 2001/18/EC. 
In light of the information package provided by Luxembourg in support of its safeguard clause and, 
having considered all relevant scientific publications, the GMO Panel concludes that: 
Luxembourg did not provide any new or additional information made available since the date of 
consent for this GM event that would affect the environmental risk assessment or the reassessment of 
existing information on the basis of new or additional scientific knowledge. New data specific to the 
safety of the nptII gene have not been provided. 
Bacterial DNA release and development of competence is expected to occur more efficiently in 
developing biofilms than in planktonic bacterial cells. However, the link of the issue of resistance in 
biofilms to the cultivation/processing of GM potato EH92-527-1 was not established by Luxembourg. 
In addition, the main barriers, limiting the transformation frequency of bacterial cells with transgenic 
plant DNA, remain. 
The risk posed by the formation of mosaic structures of aminoglycoside phosphotransferase genes 
cannot be assessed without data documenting the existence of such structures among the existing gene 
variants. Such data were not provided. 
The knowledge gaps and uncertainties highlighted in the Luxembourgeois document and the 
therapeutic relevance of kanamycin and neomycin have already been considered in the previous 
EFSA opinion on ARM genes. EFSA continually reviews the scientific literature. No new information 
on the safety of nptII gene as present in the GM potato EH92-527-1 was identified in the scientific 
literature that would cause the GMO Panel to change its previous conclusions. 
The EFSA GMO Panel concludes that no detailed grounds exist to date that would lead to 
reconsideration of its opinion on GM potato EH92-527-1. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
In February 2006, the European Food Safety Authority (EFSA) adopted an opinion related to the 
placing on the market of GM potato EH92-527-1 for cultivation and industrial starch production, 
following a notification submitted by BASF Plant Science to the Swedish Authorities. 
On 2 March 2010, the European Commission (EC) adopted a decision authorising the placing on the 
market of GM potato EH92-527-1 for cultivation and industrial starch production. 
In July 2011, Luxembourg notified to the EC its scientific argumentation justifying the 
implementation of a national safeguard measure prohibiting the placing on the market of GM potato 
EH92-527-1 for cultivation purposes in Luxembourg, according to Article 23 of Directive 2001/18/EC 
on the deliberate release in the environment of genetically modified organisms. 
In order for the EC to follow-up on this safeguard clause in accordance with Article 23 of Directive 
2001/18/EC, it was deemed appropriate by EC that EFSA would assess the scientific elements 
provided by Luxembourg. 
 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
EFSA was requested in accordance with Article 29 of Regulation (EC) No 178/2002 to assess the 
scientific information submitted by the Luxembourgeois Authorities justifying their national safeguard 
measure concerning GM potato EH92-527-1 and to identify whether these new scientific elements 
might lead the GMO Panel to reconsider its opinion on GM potato EH92-527-1 from 2006. 
Scientific opinion on safeguard clause invoked by Luxembourg on GM potato EH92-527-1 
 
EFSA Journal 2012;10(9):2874 6
ASSESSMENT 
1. INTRODUCTION 
Directive 2001/18/EC provides the possibility for Member States to invoke safeguard measures on 
specific genetically modified organisms in case in which new or additional information, made 
available since the date of the consent, or reassessment of existing information on the basis of new or 
additional scientific knowledge would affect the risk assessment of an authorised genetically modified 
organism (GMO). Provisions foreseen by Luxembourg seek to provisionally prohibit the marketing of 
potato EH92-527-1 for cultivation purposes in Luxembourg. 
The EFSA GMO Panel examined the set of supporting documents submitted by Luxembourg. In this 
respect, the GMO Panel assessed whether the submitted documents comprise new scientific 
information that would change the outcome of previously performed risk assessments and whether 
there are grounds for the GMO Panel to reconsider its opinion on GM potato EH92-527-1 (EFSA, 
2006). 
The EFSA GMO Panel looked for evidence for GMO-specific risks, taking into consideration the 
EFSA GMO Panel guidance for risk assessment of food and feed from genetically modified plants 
(EFSA, 2011) as well as any related risk assessments carried out in the past. In addition, the GMO 
Panel considered the relevance of concerns raised in the light of the most recent scientific data and 
relevant peer-reviewed publications regarding the use of specific antibiotic resistance genes as marker 
genes in GM plants. 
2. CONCERNS RAISED BY LUXEMBOURG 
The GMO Panel interprets the documentation provided by Luxembourg as raising the following 
issues: 
- DNA-containing antibiotic resistance genes derived from transgenic organisms and released via 
plant decaying processes or ingested as food or feed would increase the likelihood of contact 
between antibiotic resistance-encoding DNA and competent bacteria (section 3.1); 
- horizontal gene transfer by transformation occurs more frequently in biofilms, and antibiotic 
resistance in biofilms is of particular concern in relation to human infection (section 3.2); 
- transformation of bacteria with plant-derived DNA fragments can result in the formation of 
mosaic genes (section 3.3); 
- kanamycin and neomycin are both categorised by the World Health Organization (WHO) Expert 
Group on Critically Important Antimicrobials for Human Health as “Highly Important 
Antimicrobials” (section 3.4). 
3. RISK ASSESSMENT OF THE NPTII GENE 
3.1. The nptII gene as a risk factor 
Luxembourg claimed that additional input of DNA-containing antibiotic resistance genes derived from 
transgenic organisms over extended periods of time via plant decaying processes or uptake of food or 
feed would increase the likelihood of contact between antibiotic resistance-encoding DNA and 
competent bacteria.  
The GMO Panel has acknowledged this issue previously and assessed its implications (EFSA, 2009). 
There is no new information, either in the documentation submitted by Luxembourg or in the scientific 
literature that would cause the Panel to change its former conclusions. Therefore, the GMO Panel 
reiterates its conclusion that, taking into account all the limitations of all current methodologies of 
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detection, it can be assumed that there is, at most, a low probability of transfer of antibiotic resistance 
genes from GM plants to bacteria in the food- and feed-processing environment, in the digestive tract 
of humans and animals and in the wider environment. If this transfer were to occur, it would take place 
at an extremely low frequency. In the risk assessment, the GMO Panel took into account the 
subsequent development and dissemination of resistance among bacteria. 
3.2. Antibiotic resistance in biofilms 
Luxembourg pointed out that horizontal gene transfer by transformation occurs more frequently in 
biofilms and that antibiotic resistance in biofilms is of particular concern in relation to human 
infection. Luxembourg did not develop the relevance of the issue of resistance in biofilms to the 
cultivation/processing of GM potato EH92-527-1. 
Antibiotic resistance in biofilms is a complex, multifactorial problem, intensively studied in relation to 
hospital-acquired, implant-based infections and many persistent diseases (Li et al., 2001; Beaudoin et 
al., 2012; Mah, 2012). Although a comprehensive understanding of this antibiotic resistance is still 
lacking, research results indicate the involvement of several biofilm-specific elements, not related to 
acquired antibiotic resistance. 
Molin and Tolker-Nielsen (2003) concluded that transformation and DNA insertion by recombination 
in the recipient genome seem to be part of a biofilm-related life cycle. Bacterial DNA release and 
development of competence is expected to occur more efficiently in developing than in older biofilms. 
The frequency of transformation is estimated to be increased by 10- to 600-fold in competent 
Streptococcus mutans cells (Li et al., 2001). 
In contrast to DNA transfer by transformation between bacteria, the main barriers in bacterial 
transformation with DNA from GM plants are in the uptake of DNA from decayed plant material and 
the absence of sequence homology between bacterial and plant DNA, limiting the stabilisation of plant 
DNA in the bacterial cell to the low-frequency process of illegitimate recombination (EFSA, 2009). 
These barriers concerning the DNA transfer from plants to bacteria, which have a high impact on 
transformation frequency, remain in the developing biofilms. 
3.3. Formation of mosaic genes 
Luxembourg indicated that transformation of bacteria with plant-derived DNA fragments can result in 
the formation of mosaic4 genes. However, the Luxembourgeois Authorities did not cite any references 
supporting their hypothesis that nptII mosaic gene structures would exist with altered substrate 
specificity of the corresponding enzymes. 
The GMO Panel is not aware of any studies reporting formation of mosaic genes between the several 
genes encoding aminoglycoside phosphotransferases. The Panel also notes that the example of 
formation of mosaic genes, as indicated by Luxembourg, was for penicillin-binding proteins, and 
specifically for a bacterial species in which natural genetic transformation is responsible for high 
genomic plasticity (Streptococcus pneumoniae). Extrapolation to aminoglycoside phosphotransferases 
is not supported by published scientific literature. Existing data do show that several conserved motifs 
are essential to the catalytic activity in the aminoglycoside phosphotransferase family of enzymes 
(reviewed by Shaw et al., 1993). 
The formation of mosaic structures from the transfer of the nptII gene from plant to bacteria would be 
expected to occur with a frequency several orders of magnitude lower compared with that between 
bacteria. At the moment, no mosaic structures of aminoglycoside phophotransferase genes are found 
in bacteria although these genes are widespread in many environments. 
                                                     
4 The term “mosaic” derives from the pattern of interspersed blocks of nucleotide sequence that have different evolutionary 
histories but are found combined in a gene allele subsequent to recombination events (Hollingshead et al, 2000). 
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The GMO Panel concludes that the risk posed by the formation of mosaic structures of 
aminoglycoside phosphotransferase genes cannot be assessed without data documenting the presence 
of such structures among the existing gene variants. 
3.4. Therapeutic relevance of kanamycin and neomycin in human and veterinary medicine 
Luxembourg pointed out that kanamycin and neomycin are both categorised by the WHO Expert 
Group on Critically Important Antimicrobials for Human Health as “Highly Important 
Antimicrobials”. The GMO Panel has already acknowledged this statement (EFSA, 2009; EFSA, 
2012). 
The GMO Panel points out that the use of antibiotics is a key factor in the selection and dissemination 
of antibiotic resistance genes in the immediate environment. While the key role of selection by 
antibiotic usage in the development of resistance seems indisputable, some knowledge gaps remain 
regarding the understanding of the natural reservoir of antibiotic resistance genes and their role in 
natural bacterial communities not exposed to industrially produced antibiotics, as concluded 
previously (EFSA, 2009). 
In conclusion, the EFSA GMO Panel considers that the information submitted by Luxembourg in 
relation to the therapeutic relevance of kanamycin and neomycin was addressed in the EFSA’s opinion 
on antibiotic resistance marker genes (EFSA, 2009) and that no additional data have been presented to 
warrant reconsideration. 
CONCLUSIONS 
The EFSA GMO Panel examined the document submitted by Luxembourg. The Panel assessed 
whether the document contained new scientific information and concluded that: 
Luxembourg did not provide any new or additional information made available since the date of 
consent for this GM event that would affect the environmental risk assessment or the reassessment of 
existing information on the basis of new or additional scientific knowledge.5 New data specific to the 
safety of the nptII gene have not been provided. 
Bacterial DNA release and development of competence are expected to occur more efficiently in 
developing biofilms than in planktonic bacterial cells. However, the link of the issue of resistance in 
biofilms to the cultivation/processing of GM potato EH92-527-1 was not established by Luxembourg. 
In addition, the main barriers, limiting the transformation frequency of bacterial cells with transgenic 
plant DNA, remain. 
The risk posed by the formation of mosaic structures of aminoglycoside phosphotransferase genes 
cannot be assessed without data documenting the existence of such structures among the existing gene 
variants. Such data were not provided. 
The knowledge gaps and uncertainties highlighted in the Luxembourgeois document and the 
therapeutic relevance of kanamycin and neomycin have already been considered in the previous EFSA 
opinion on antibiotic resistance marker genes. EFSA continually reviews the scientific literature. No 
new information on the safety of the nptII gene, as present in the GM potato EH92-527-1, was 
identified in the scientific literature that would cause the GMO Panel to change its earlier conclusions. 
The EFSA GMO Panel concludes that no detailed grounds exist to date that would lead to 
reconsideration of its opinion on GM potato EH92-527-1. 
                                                     
5 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the 
environment of genetically modified organisms and repealing Council Directive 90/220/EEC. Official Journal of the 
European Communities L106: 1–38. (Article 23). 
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DOCUMENTATION PROVIDED TO EFSA 
1. Letter, received 23 May 2012, with supporting document from Ladislav Miko, Deputy Director-
General for the Food Chain in the EC, to Catherine Geslain-Lanéelle, Executive Director EFSA 
(Ref. SANCO/E1/MD/mp Ares(2012) 616525), requesting the assessment by EFSA of the 
scientific elements provided by Luxembourg in support of its decision to implement a national 
safeguard measure under Article 23 of Directive 2001/18/EC for GM potato EH92-527-1 and 
comprising the following supporting document: 
- Scientific justification for the ban on cultivating genetically modified potatoes (Solanum 
tuberosum L. line EH92-527-1, notification C/SE/96/3501) in the Grand Duchy of 
Luxembourg. 
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